Guidelines for vasodilator therapy of congestive heart failure in infants and children.
D002216:Captopril / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004656:Enalapril / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006331:Heart Diseases / Q000188:drug therapy; D006333:Heart Failure / Q000188:drug therapy*; D006352:Heart Ventricles; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007223:Infant; D009543:Nifedipine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005996:Nitroglycerin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D009599:Nitroprusside / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D010646:Phentolamine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011224:Prazosin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*
D014665:Vasodilator Agents; D009599:Nitroprusside; D006830:Hydralazine; D004656:Enalapril; D002216:Captopril; D005996:Nitroglycerin; D009543:Nifedipine; D011224:Prazosin; D010646:Phentolamine